References
- Safian RD, Textor SC. Renal-artery stenosis. New Engl J Med 2001;344:431-42
- Wheatley K, Ives N, Gray R, et al. Revascularization versus medical therapy for renal-artery stenosis. New Engl J Med 2009;361:1953-62
- Dalla Vestra M, Pozza G, Mosca A, et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr Metab 2004;17:259-66
- Robles NR, Ocon J, Gomez CF, et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail 2005;27:73-80
- Wu JR, Liou SF, Lin SW, et al. Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellular reactive oxygen species and inactivating Ras-ERK1/2 signaling. Pharm Res 2009;59:48-56
- Jiang XJ, Wu HY, Ming GH, et al. Clinical results of stent revascularization as treatment for renal artery stenosis during 6 months of follow-up. Zhonghua Xin Xue Guan Bing Za Zhi 2005;33:224-7
- Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992;19:403-18
- Coen G, Moscaritolo E, Catalano C, et al. Atherosclerotic renal artery stenosis: one year outcome of total and separate kidney function following stenting. BMC Nephrol 2004;5:15
- Sapoval M, Tamari I, Goffette P, et al. One year clinical outcomes of renal artery stenting: the results of ODORI Registry. Cardiovasc Surg Radiol 2010;33:475-83
- Takumi T, Mathew V, Barsness GW, et al. The association between renal atherosclerotic plaque characteristics and renal function before and after renal artery surgery. Mayo Clin Proc 2011;86:1165-72
- Menne J, Park JK, Agrawal R, et al. Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers. FASEB J 2006;20:994-6
- Sabbatini M, Vitaioli L, Baldoni E, et al. Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats. J Pharmacol Exp Ther 2000;294:948-54
- Menne J, Park JK, Boehne M, et al. Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-alpha-deficient diabetic mice. Diabetes 2004;53:2101-9
- Muth JN, Bodi I, Lewis W, et al. A Ca(2+)-dependent transgenic model of cardiac hypertrophy: A role for protein kinase C alpha. Circulation 2001;103:140-7
- Hahn HS, Marreez Y, Odley A, et al. Protein kinase C alpha negatively regulates systolic and diastolic function in pathological hypertrophy. Circulation Res 2003;93:1111-19
- Braz JC, Gregory K, Pathak A, et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med 2004;10:248-54
- Robles NR. Calcium antagonists and renal failure progression. Ren Fail 2008;30:247-55
- Egan CG, Pontremoli R. Role of the fixed-dose combination lercanidipine–enalapril in renal protection. J Nephrol 2011;24:428-37
- Nordmann AJ, Woo K, Parkes R, et al. Balloon angioplasty or medical therapy for hypertensive patients with atherosclerotic renal artery stenosis? A meta-analysis of randomized controlled trials. Am J Med 2003;114:44-50
- Barrios V, Escobar C, de la Figuera M, et al. High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study. Int J Clin Pract 2008;62:723-8
- Rosa J, Somloova Z, Petrak O, et al. Peripheral arterial stiffness in primary aldosteronism. Physiol Res 2012;61:461-8
- Burnier M. Renal protection with calcium antagonists: the role of lercanidipine. Curr Med Res Opin 2013;29:1727-35